Zogenix, Inc. (NASDAQ:ZGNX) Shares Bought by Xact Kapitalforvaltning AB

Xact Kapitalforvaltning AB raised its holdings in Zogenix, Inc. (NASDAQ:ZGNX) by 100.0% during the first quarter, HoldingsChannel reports. The firm owned 14,600 shares of the company’s stock after acquiring an additional 7,300 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Zogenix were worth $803,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Swiss National Bank boosted its holdings in shares of Zogenix by 3.4% in the 1st quarter. Swiss National Bank now owns 76,500 shares of the company’s stock valued at $4,208,000 after purchasing an additional 2,500 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Zogenix by 19.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 560,475 shares of the company’s stock valued at $30,831,000 after purchasing an additional 90,015 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of Zogenix by 22.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,300 shares of the company’s stock valued at $666,000 after purchasing an additional 2,600 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Zogenix by 8.9% in the 1st quarter. Wells Fargo & Company MN now owns 42,290 shares of the company’s stock valued at $2,327,000 after purchasing an additional 3,449 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its holdings in shares of Zogenix by 9.2% in the 1st quarter. Pictet Asset Management Ltd. now owns 444,130 shares of the company’s stock valued at $24,432,000 after purchasing an additional 37,443 shares in the last quarter.

A number of equities research analysts have weighed in on the company. BidaskClub raised Zogenix from a “hold” rating to a “buy” rating in a report on Friday, June 7th. ValuEngine downgraded Zogenix from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. LADENBURG THALM/SH SH set a $50.00 price objective on Zogenix and gave the company a “buy” rating in a report on Tuesday, April 9th. Svb Leerink cut their price objective on Zogenix from $60.00 to $48.00 and set an “outperform” rating on the stock in a report on Tuesday, April 9th. Finally, Piper Jaffray Companies cut their price objective on Zogenix from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Zogenix currently has an average rating of “Buy” and a consensus target price of $61.17.



Shares of NASDAQ ZGNX traded up $0.01 during mid-day trading on Wednesday, hitting $39.25. 10,444 shares of the stock traded hands, compared to its average volume of 633,794. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.02. Zogenix, Inc. has a twelve month low of $33.43 and a twelve month high of $62.75. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -12.12 and a beta of 1.91.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.83) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.02. On average, research analysts anticipate that Zogenix, Inc. will post -3.62 earnings per share for the current fiscal year.

In related news, Director Roger Hawley sold 60,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $52.99, for a total transaction of $3,179,400.00. Following the completion of the transaction, the director now directly owns 49,364 shares of the company’s stock, valued at approximately $2,615,798.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://dakotafinancialnews.com/2019/06/12/zogenix-inc-nasdaqzgnx-shares-bought-by-xact-kapitalforvaltning-ab.html.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Read More: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.